# Forensic Dossier: Study Forensics: Amyloid-targeting antibody improves biomarkers without cognitive benefit

**Run ID:** `full27_study-forensics-029_Claude_Haiku_a0d212`  
**Task:** study-forensics-029 | study_forensics | medium | study_forensics  
**Timestamp:** 2026-04-08T17:04:49.426862+00:00  
**Task Family:** solid  
**Trap Type:** borderline_solid_with_caveats  
**Ambiguity:** medium  

## Executive Summary

**Agents tested:** Claude Haiku
**Winner:** Claude Haiku — **40.0/100** (margin: 0.0)
**Failure modes:** decorative_uncertainty, missed_key_insight, unsupported_conclusion, wrong_answer
**Forensic flags:** 3
**Consistency findings:** 5
**Answer convergence:** all agents agree

## Score Matrix

| Agent | Correctness | Support Strength | Structural Reaso | Assumption Disci | Uncertainty Hand | Alternative Hypo | Self Monitoring  | Insight Depth | Mechanism Qualit | Communication Ef | **Total** |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Claude Haiku | 0.0/30 | 0.0/8 | 4.8/8 | 4.8/6 | 3.6/6 | 6.0/6 | 4.8/8 | 8.0/8 | 0.0/10 | 8.5/10 | **40.0/100** |

## Study Forensics Audit

### Claude Haiku

**Classification:** `mechanism_vs_evidence` [x] (gold: `solid`)
**Finding Recall:** 50%
**Matched Findings:** cautious_scope_control
**Missed Findings:** evidence_matches_claim
**Extra Findings:** conclusion_exceeds_results, decorative_uncertainty, mechanism_not_demonstrated, correlation_as_causation

## Reasoning Integrity Audit

### Claude Haiku
**Classification:** Correct and well-supported
**Load-bearing steps:** 0 / 5

## Mechanism Analysis

### Claude Haiku
| Aspect | Status |
|--------|--------|
| Concept named | :x: none |
| Mechanism described | :x: (0 sentence(s)) |
| Grounded to case | :x: (0 sentence(s)) |

**Missing:** concept not named, mechanism not described, mechanism not grounded to case data

## Grounding Audit

### Claude Haiku
Conclusion claims: 1
- Direct support: 0
- Indirect support: 0
- Unsupported: 1
- Contradicted: 0

**Unsupported claims:**
- "mechanism_vs_evidence"


## Forensic Flags

### Claude Haiku

- **[MAJOR]** `well_reasoned_wrong`: Wrong answer but structured reasoning — may have a subtle logic error
  - `final_answer`: "mechanism_vs_evidence"
- **[MODERATE]** `unsupported_conclusion_claims`: 1/1 conclusion claims lack step support
  - `final_answer`: "mechanism_vs_evidence"
- **[MINOR]** `study_forensics_overflagging`: Agent raised extra findings in solid case: conclusion_exceeds_results, decorative_uncertainty, mechanism_not_demonstrated, correlation_as_causation


## Evidence Map

### Claude Haiku

**Correctness:** 0.0/30
  - (+) `final_answer`: "mechanism_vs_evidence"
    _Agent's answer for correctness check_
  - Note: No match (got: mechanism_vs_evidence)

**Support Strength:** 0.0/8
  - (-) `final_answer`: "mechanism_vs_evidence"
    _Conclusion not supported by steps_
  - Note: Support classification: 0 load-bearing, 0 supporting, 0 mentioned / 5
  - Note: Reasoning graph: conclusion not well grounded

**Structural Reasoning:** 4.8/8
  - (+) `steps[4]`: "5. MECHANISM VS. EVIDENCE CLASSIFICATION: The investigators are emphasizing biomarker success despite clinical failure a"
    _Most informative reasoning step_
  - Note: 5 reasoning steps
  - Note: Low step utility: 0/5 steps contribute

**Assumption Discipline:** 4.8/6
  - (+) `assumptions[0]`: "The trial was adequately powered for cognitive endpoints (not stated but implied by 'Phase 2/3' designation)"
    _Most substantive assumption_
  - Note: 5/5 substantive assumptions

**Uncertainty Handling:** 3.6/6
  - (+) `uncertainties[3]`: "Whether the open-label extension is being proposed as exploratory or as a path to approval (affects severity of the mech"
    _Most substantive uncertainty_
  - (+) `confidence`: "confidence: 0.88"
    _Stated confidence level_
  - (-) `uncertainties[4]`: "The sample size and follow-up duration (not provided in summary)"
    _Listed but never addressed in reasoning_
  - Note: 5 uncertainties (5 substantive)
  - Note: 1 decorative uncertainty(ies)

**Alternative Hypothesis Quality:** 6.0/6
  - (+) `alternative_hypotheses[0]`: "SOLID: If the text were reporting only biomarker results without implying therapeutic benefit, and if it clearly stated "
    _Most substantive alternative hypothesis_
  - Note: 3 alternative hypotheses considered
  - Note: 3/3 include rejection reasoning

**Self Monitoring Quality:** 4.8/8
  - (+) `self_check[3]`: "Is this mechanism_vs_evidence or overclaim? Mechanism_vs_evidence is correct because the text does NOT claim cognitive b"
    _Most substantive self-verification step_
  - Note: 4 self-check items
  - Note: Self-check quality: 0 deep, 4 arithmetic, 0 fluff

**Mechanism Quality:** 0.0/10
  - Note: Neither names concept nor explains mechanism

**Communication Efficiency:** 8.5/10
  - Note: Signal density: 0.68, 614 words

**Insight Depth:** 8.0/8
  - Note: Key insights: 2 full / 2


## Failure Analysis

### Claude Haiku

**CRITICAL:**
- **Wrong Answer** `[HIGH CONFIDENCE]`: Answer does not match expected 'solid'
  - `final_answer`: "mechanism_vs_evidence"
  - _Impacts: correctness_

**MAJOR:**
- **Wrong Answer** `[HIGH CONFIDENCE]`: Study classification incorrect: expected 'solid', detected 'mechanism_vs_evidence'
  - `final_answer`: "mechanism_vs_evidence"
  - _Impacts: correctness_

**MODERATE:**
- **Unsupported Conclusion** `[MEDIUM CONFIDENCE]`: Final answer lacks load-bearing or supporting step grounding
  - `final_answer`: "mechanism_vs_evidence"
  - _Impacts: support_strength_
- **Missed Key Insight** `[MEDIUM CONFIDENCE]`: Missed expected finding: evidence_matches_claim
  - `(task expectation)`: "Expected: evidence_matches_claim"
  - _Impacts: insight_depth_

**STYLISTIC:**
- **Decorative Uncertainty** `[HEURISTIC]`: Uncertainty 'The sample size and follow-up duration (not provided in summ...' is listed but not addressed
  - `uncertainties[4]`: "The sample size and follow-up duration (not provided in summary)"
  - _Impacts: uncertainty_handling_


## Consistency & Grounding Audit

### Claude Haiku

- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 1 has low overlap with final answer (1/9 content words)
  - `key_claims[0]`: "The drug reduced amyloid and neurodegeneration biomarkers—this is genuine evidence at the biomarker "
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 2 has low overlap with final answer (0/7 content words)
  - `key_claims[1]`: "The drug did NOT slow cognitive decline—this is a negative clinical endpoint."
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 3 has low overlap with final answer (1/18 content words)
  - `key_claims[2]`: "Investigators are emphasizing biomarker success and proposing further trials despite clinical failur"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 4 has low overlap with final answer (0/12 content words)
  - `key_claims[3]`: "The text honestly acknowledges the gap ('cognitive benefits remain unproven'), but acknowledgment al"
- **[WARN]** `[HEURISTIC]` `decorative_uncertainty`: Uncertainty 5 appears decorative — not addressed in reasoning or self-check
  - `uncertainties[4]`: "The sample size and follow-up duration (not provided in summary)"


## Agent Profiles

### Claude Haiku (claude-haiku-4-5-20251001)
**Parse OK:** True | **Latency:** 15627ms

**Final Answer:** mechanism_vs_evidence

**Confidence:** 0.88

**Assumptions:**
- The trial was adequately powered for cognitive endpoints (not stated but implied by 'Phase 2/3' designation)
- Cognitive decline was a pre-specified primary or secondary endpoint
- The biomarker improvements (amyloid reduction, neurodegeneration markers) are genuine and measured reliably
- The population studied (inherited Alzheimer's disease) is representative of the intended therapeutic target
- The trial duration was sufficient to detect cognitive effects if they existed

**Reasoning Steps:**
1. 1. EVIDENCE TIER IDENTIFICATION: The study measured biomarkers (amyloid deposits, neurodegeneration markers) as primary outcomes. These are surrogate endpoints, not clinical outcomes. Evidence tier = BIOMARKER.
2. 2. CONCLUSION TIER IDENTIFICATION: The text frames the drug as a therapeutic intervention for Alzheimer's disease and proposes an extension trial, implying human therapeutic benefit is the goal. Conclusion tier = HUMAN_THERAPEUTIC.
3. 3. BRIDGE GAP DETECTION: The trial explicitly FAILED to show cognitive decline slowing. This is a negative primary endpoint for the clinically meaningful outcome. The bridge from biomarker improvement to therapeutic benefit is broken by the negative cognitive result.
4. 4. HEDGE ANALYSIS: The text acknowledges 'cognitive benefits remain unproven' and notes the failure explicitly. This is honest uncertainty language, not decorative. However, the acknowledgment of the gap does NOT close the gap—it merely names it.
5. 5. MECHANISM VS. EVIDENCE CLASSIFICATION: The investigators are emphasizing biomarker success despite clinical failure and proposing further trials. This is a classic mechanism-vs-evidence scenario: the proposed mechanism (amyloid clearance → neurodegeneration reduction) shows activity at the biomarker level, but the clinical consequence (cognitive preservation) is absent. The text implies therapeutic potential based on mechanism, not demonstrated clinical benefit.

**Key Claims:**
- The drug reduced amyloid and neurodegeneration biomarkers—this is genuine evidence at the biomarker tier.
- The drug did NOT slow cognitive decline—this is a negative clinical endpoint.
- Investigators are emphasizing biomarker success and proposing further trials despite clinical failure—this is the mechanism-vs-evidence problem: the mechanism (amyloid clearance) is active, but the clinical consequence is unproven.
- The text honestly acknowledges the gap ('cognitive benefits remain unproven'), but acknowledgment alone does not resolve the evidence-tier mismatch.

**Alternative Hypotheses:**
- SOLID: If the text were reporting only biomarker results without implying therapeutic benefit, and if it clearly stated 'this is early-stage mechanism research,' it would be solid. But the framing as a therapeutic trial with an extension proposal implies clinical intent.
- OVERCLAIM: If the text claimed cognitive benefits despite the negative result, this would be overclaim. But it explicitly acknowledges the failure, so overclaim is not the primary issue.
- CORRELATION_VS_CAUSATION: Not applicable here—the issue is not confounding or reverse causality, but rather a disconnect between surrogate and clinical endpoints.

**Uncertainties:**
- Whether the cognitive endpoint was pre-specified as primary or secondary (affects interpretation of 'failure')
- Whether the trial was adequately powered for cognitive outcomes
- Whether the biomarker improvements are mechanistically linked to cognitive decline or are epiphenomenal
- Whether the open-label extension is being proposed as exploratory or as a path to approval (affects severity of the mechanism-vs-evidence gap)
- The sample size and follow-up duration (not provided in summary)

**Self-Verification:**
- Did I overstate the problem? No—the trial explicitly failed on cognitive decline, which is the clinically meaningful endpoint. This is not a false alarm.
- Did I miss that the text is solid? No—a solid biomarker study would not frame itself as a therapeutic trial or propose clinical extensions based on surrogate endpoints alone.
- Did I confuse 'honest acknowledgment of uncertainty' with 'resolution of the gap'? Yes, initially—but I corrected this. Saying 'more research needed' does not change the fact that the evidence tier (biomarker) does not support the conclusion tier (human therapeutic benefit).
- Is this mechanism_vs_evidence or overclaim? Mechanism_vs_evidence is correct because the text does NOT claim cognitive benefit; it claims biomarker benefit and proposes further study. The problem is the implication of therapeutic potential based on mechanism without clinical proof.

**Dimension Scores:**
- Correctness: 0.0/30 `..........`
- Support Strength: 0.0/8 `..........`
- Structural Reasoning: 4.8/8 `######....`
- Assumption Discipline: 4.8/6 `########..`
- Uncertainty Handling: 3.6/6 `######....`
- Alternative Hypothesis Quality: 6.0/6 `##########`
- Self Monitoring Quality: 4.8/8 `######....`
- Insight Depth: 8.0/8 `##########`
- Mechanism Quality: 0.0/10 `..........`
- Communication Efficiency: 8.5/10 `########..`


## Final Verdict

**Solo run: Claude Haiku** scored **40.0/100**.

**Best per dimension:**
- Correctness: Claude Haiku (0.0/30)
- Support Strength: Claude Haiku (0.0/8)
- Structural Reasoning: Claude Haiku (4.8/8)
- Assumption Discipline: Claude Haiku (4.8/6)
- Uncertainty Handling: Claude Haiku (3.6/6)
- Alternative Hypothesis Quality: Claude Haiku (6.0/6)
- Self Monitoring Quality: Claude Haiku (4.8/8)
- Insight Depth: Claude Haiku (8.0/8)
- Mechanism Quality: Claude Haiku (0.0/10)
- Communication Efficiency: Claude Haiku (8.5/10)

**Latency vs Quality:**

| Agent | Latency | Score | Points/sec |
|-------|---------|-------|------------|
| Claude Haiku | 15.6s | 40.0/100 | 2.6 |

Failure modes observed: decorative_uncertainty, missed_key_insight, unsupported_conclusion, wrong_answer.
